ABCC1 and cancer: MRP1 has been described for the first time, in 1992 by Cole et al. This 190 kDa glycoprotein that has been shown to export a wide range of substrates including bioactive compounds, signaling molecules, metabolites, anti-cancer drugs, and xenobiotics, thus conferring multidrug resistance in cancer.